JP2009178162A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009178162A5 JP2009178162A5 JP2009068078A JP2009068078A JP2009178162A5 JP 2009178162 A5 JP2009178162 A5 JP 2009178162A5 JP 2009068078 A JP2009068078 A JP 2009068078A JP 2009068078 A JP2009068078 A JP 2009068078A JP 2009178162 A5 JP2009178162 A5 JP 2009178162A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- peptide
- medicament
- amyloid deposition
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 3
- 230000003941 amyloidogenesis Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000006933 amyloid-beta aggregation Effects 0.000 claims 1
- 230000007278 cognition impairment Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21253400P | 2000-06-20 | 2000-06-20 | |
| US60/212,534 | 2000-06-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002503093A Division JP4938956B2 (ja) | 2000-06-20 | 2001-06-19 | 神経変性性障害のトランスジェニック動物モデル |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009178162A JP2009178162A (ja) | 2009-08-13 |
| JP2009178162A5 true JP2009178162A5 (enExample) | 2011-07-28 |
| JP5070236B2 JP5070236B2 (ja) | 2012-11-07 |
Family
ID=22791418
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002503093A Expired - Lifetime JP4938956B2 (ja) | 2000-06-20 | 2001-06-19 | 神経変性性障害のトランスジェニック動物モデル |
| JP2009068078A Expired - Lifetime JP5070236B2 (ja) | 2000-06-20 | 2009-03-19 | 神経変性性障害のトランスジェニック動物モデル |
| JP2011132718A Withdrawn JP2011172600A (ja) | 2000-06-20 | 2011-06-14 | 神経変性性障害のトランスジェニック動物モデル |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002503093A Expired - Lifetime JP4938956B2 (ja) | 2000-06-20 | 2001-06-19 | 神経変性性障害のトランスジェニック動物モデル |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011132718A Withdrawn JP2011172600A (ja) | 2000-06-20 | 2011-06-14 | 神経変性性障害のトランスジェニック動物モデル |
Country Status (13)
| Country | Link |
|---|---|
| EP (3) | EP2263453B1 (enExample) |
| JP (3) | JP4938956B2 (enExample) |
| AT (2) | ATE499832T1 (enExample) |
| AU (1) | AU2001270377A1 (enExample) |
| CA (1) | CA2407847C (enExample) |
| CY (1) | CY1105122T1 (enExample) |
| DE (2) | DE60144164D1 (enExample) |
| DK (1) | DK1292187T3 (enExample) |
| ES (1) | ES2262662T3 (enExample) |
| MX (1) | MXPA02011516A (enExample) |
| PT (1) | PT1292187E (enExample) |
| SI (1) | SI1292187T1 (enExample) |
| WO (1) | WO2001097607A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100994748B1 (ko) | 2002-04-19 | 2010-11-17 | 더 가버닝 카운실 오브 더 유니버시티 오브 토론토 | 알쯔하이머병의 치료를 위한 면역학적 방법 및 조성물 |
| US7544855B2 (en) * | 2004-04-23 | 2009-06-09 | Buck Institute | Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664 |
| JP4590638B2 (ja) * | 2006-03-20 | 2010-12-01 | 国立大学法人鳥取大学 | 家族性筋萎縮性側索硬化症（ｆａｌｓ）発症するトランスジェニックマウス |
| CL2007002908A1 (es) | 2007-10-09 | 2008-05-30 | Univ Concepcion | Procedimiento electroquimico in vitro para evaluar capacidad neurotoxica de estructuras, principios activos y/o compuestos de interes en celulas vivas y que comprende medir y cuantificar los parametros electricos en membranas expuestas a dichos agreg |
| ES2445446T3 (es) * | 2007-11-01 | 2014-03-03 | F. Hoffmann-La Roche Ag | Animales no humanos cuatro veces transgénicos |
| WO2010054324A2 (en) * | 2008-11-10 | 2010-05-14 | The Regents Of The University Of Colorado, A Body Corporate | Methods for treating clinical conditions associated with lipoprotein lipase activity |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU702293B2 (en) | 1993-10-27 | 1999-02-18 | Athena Neurosciences, Inc. | Transgenic animals harboring APP allele having Swedish mutation |
| JPH07132033A (ja) | 1993-11-12 | 1995-05-23 | Hoechst Japan Ltd | アルツハイマー病モデルトランスジェニック動物 |
| US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| WO1995020666A2 (en) * | 1994-01-27 | 1995-08-03 | Regents Of The University Of Minnesota | Transgenic non-human mammals with progressive neurologic disease |
| CA2221986A1 (en) * | 1995-06-07 | 1996-12-19 | Athena Neurosciences, Inc. | Method for identifying alzheimer's disease therapeutics using transgenic animal models |
| US5894078A (en) | 1996-02-26 | 1999-04-13 | Advanced Bioconcept, Inc. | Transgenic mouse expressing C-100 app |
| WO1999009150A1 (en) * | 1996-08-15 | 1999-02-25 | Bayer Corporation | Method of introducing modifications into a gene |
| US5898094A (en) * | 1996-10-21 | 1999-04-27 | University Of South Florida | Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
-
2001
- 2001-06-19 DE DE60144164T patent/DE60144164D1/de not_active Expired - Lifetime
- 2001-06-19 SI SI200130579T patent/SI1292187T1/sl unknown
- 2001-06-19 PT PT01949132T patent/PT1292187E/pt unknown
- 2001-06-19 AU AU2001270377A patent/AU2001270377A1/en not_active Abandoned
- 2001-06-19 AT AT06007794T patent/ATE499832T1/de not_active IP Right Cessation
- 2001-06-19 MX MXPA02011516A patent/MXPA02011516A/es not_active Application Discontinuation
- 2001-06-19 EP EP10182160.1A patent/EP2263453B1/en not_active Expired - Lifetime
- 2001-06-19 JP JP2002503093A patent/JP4938956B2/ja not_active Expired - Lifetime
- 2001-06-19 DK DK01949132T patent/DK1292187T3/da active
- 2001-06-19 CA CA2407847A patent/CA2407847C/en not_active Expired - Lifetime
- 2001-06-19 EP EP01949132A patent/EP1292187B1/en not_active Expired - Lifetime
- 2001-06-19 ES ES01949132T patent/ES2262662T3/es not_active Expired - Lifetime
- 2001-06-19 AT AT01949132T patent/ATE323408T1/de not_active IP Right Cessation
- 2001-06-19 WO PCT/CA2001/000900 patent/WO2001097607A2/en not_active Ceased
- 2001-06-19 EP EP06007794A patent/EP1728423B1/en not_active Expired - Lifetime
- 2001-06-19 DE DE60118913T patent/DE60118913T2/de not_active Expired - Lifetime
-
2006
- 2006-07-19 CY CY20061101003T patent/CY1105122T1/el unknown
-
2009
- 2009-03-19 JP JP2009068078A patent/JP5070236B2/ja not_active Expired - Lifetime
-
2011
- 2011-06-14 JP JP2011132718A patent/JP2011172600A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017075173A5 (enExample) | ||
| EP3563849A3 (en) | Combination therapies for the treatment of alzheimer's disease and related disorders | |
| MX2020012932A (es) | Nuevos compuestos para diagnostico. | |
| SA519410311B1 (ar) | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها | |
| EA201890313A1 (ru) | Гуманизированные антитела к пироглутаматному варианту бета-амилоида | |
| EP1838320A4 (en) | CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL PROBLEMS | |
| EP2683382A4 (en) | DOSAGE SCHEMES FOR THE TREATMENT OF MORBUS FABRY | |
| PH12013500615A1 (en) | Phosphospecific antibodies recognising tau | |
| EP2504036A4 (en) | DEVICE FOR STEP-BY-STEP COMPRESSION FOR THE TREATMENT OF CIRCULAR DISEASES | |
| NO20084531L (no) | Bruk av flibanserin for behandling av post-menopause seksuell lyst lidelser | |
| EA200870556A1 (ru) | Комбинированная терапия в лечении эпилепсии и родственных расстройств | |
| JP2015501783A5 (enExample) | ||
| MX354662B (es) | Anticuerpos fosfoespecificos que reconocen la tau. | |
| EP2306956A4 (en) | RANDOM VIBRATION FOR THE TREATMENT OF BLEACHING TROUBLES | |
| EP2282795A4 (en) | TREATMENT OF RESPIRATORY DISEASES | |
| GT201100283A (es) | Anticuerpos humanizados especificos de la forma protofibrilar del péptido beta-amiloide | |
| EP2822566A4 (en) | INHALATION OF STICK OXIDE FOR THE TREATMENT OF RESPIRATORY DISEASES | |
| WO2009149486A3 (en) | Compounds for treating beta-amyloidoses | |
| IL217901B (en) | Use of laquinimod or a laquinimod salt in the manufacture of a drug for the treatment of bdnf-related diseases | |
| JP2011520900A5 (enExample) | ||
| WO2011072257A3 (en) | Amyloid binding agents | |
| EP2438923A4 (en) | COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF OBSERVATION-BASED ILLNESSES BY THE ACTIVATION OF AMPK AND WITH 2,5-BIS-ARYL-3,4-DIMETHYLTETRAHYDROFURANLIGNANES AS ACTIVE SUBSTANCES | |
| ES2489297B1 (es) | Benzotiazoles sustituidos y sus aplicaciones terapeuticas para el tratamiento de enfermedades humanas | |
| EP3956346A4 (en) | NEW RADIOLABALED DIAGNOSTIC AND THERAPEUTIC COMPOUNDS TARGETING CXCR4 | |
| CN110114079A (zh) | 一种预防和治疗肥胖症的方法和药物 |